Stock screener

ANAB

Conviction 64HealthcareScan · Thu, Jun 25, 2026
ANAB$59.63+1.97%
ResistanceSupportVol 14
63 bars
Vol MA14 543.53K
Mar 26Apr 14May 1May 19Jun 8Jun 25
ANAPTYSBIO, INCPHARMACEUTICAL PREPARATIONSwww.anaptysbio.com
Price59.63
Change+1.97%
Gap+2.98%
Rel volume1.73×
Avg volume576.7K
Avg $ vol31.86M
SMA 2055.24
SMA 5059.59
SMA 20048.48
Price vs 50+0.07%
Price vs 200+23.01%
MA stackbullish
50/200 cross
Supertrenddown · 60.67
RSI (14)56
MACD hist0.92
MACD crossbull · 8d
Stoch %K / %D78 / 74
ADX (14)19
+DI / −DI25 / 18
RSI divergence
MACD divergence
ATR %+5.37%
ADR %4.89%
52w high70.22
52w low19.40
From 52w high-15.08%
Above 52w low+207.37%
New 52w highNo
SqueezeOff
Bollinger width23.85%
%B0.83
Donchian pos78.06%
Donchian high62.32
Donchian low50.06
AVWAP (52w high)60.07
vs AVWAP high-0.74%
AVWAP (52w low)48.95
vs AVWAP low+21.81%
OBV trendFlat
Chaikin MF (20)-0.18
Today vs 20d1.73×
Avg vol (14d)543.53K
Avg vol (20d)576.7K
Avg $ vol (20d)31.86M
Market cap1.74B
RS 3m (vs SPY)-19.46%
RS 6m (vs SPY)+11.42%
RS line new highNo
Trend template7/8
Technical rank74.1
1 week+5.04%
1 month+3.22%
3 months-8.81%
6 months+18.48%
1 year+155.70%
YTD+32.66%
P/E-131.14
P/B136.13
P/S7.40
P/FCF88.49
EPS-0.4600
Div yield
ROE-103.80%
ROA-4.01%
Debt/Eq
Current7.58
EV/EBITDA30.68
Gross margin
Net margin-5.64%
Rev growth157.01%
EPS growth90.89%
Price target79.86
Target upside33.93%
Analyst ratingBuy
Institutional104.05%
Ent. value1.49B
Revenue25.56M
Net income-52.88M
Gross profit
Free cash flow19.61M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out29.1M
Employees104
ListedThu, Jan 26, 2017
Free float17.05M
Float %61.6%
Short interest4.82M
Days to cover9.8d
Short volume76.3%
Squeeze score96 / 100
Next earningsWed, Aug 5, 2026 (41d)
EPS forecast−$0.22 · 3 est
Last EPS vs est−$1.84 vs −$0.32
Last surprise-475.0% miss
Setup gradeB
Conviction64 / 100
Pattern quality
Tech rank74.1 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance71.42
Support50.12
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ANAB

All disclosures →
No recent disclosed trades by Congress in ANAB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ANAB · 6 buys · 4 sells

InsiderSideShares
RENTON HOLLINGS
Director · Common Stock · 2026-06-15
Exercise6.03K
RENTON HOLLINGS
Director · Restricted Stock Unit · 2026-06-15
Exercise6.03K
Orwin John A
Director · Common Stock · 2026-06-15
Exercise6.03K
Orwin John A
Director · Restricted Stock Unit · 2026-06-15
Exercise6.03K
Schmid John P.
Director · Common Stock · 2026-06-15
Exercise6.03K
Schmid John P.
Director · Restricted Stock Unit · 2026-06-15
Exercise6.03K
Murphy Christopher M.
Chief Financial Officer · Restricted Stock Units · 2026-05-11
Grant25.77K
Hughes Owen
Director · Restricted Stock Units · 2026-05-11
Grant11.25K
GRAY SUSANNAH
Director · Restricted Stock Unit · 2026-04-27
Grant11.25K
Faga Daniel
President, CEO · Employee Stock Option (right to buy) · 2026-04-20
Disposition11K

SEC filings

EDGAR filings in ANAB · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.